SEC Form 4 · accession 0000899243-16-017487
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas O Daniel
Director
Period of report
Apr 1, 2016
Accepted (ET)
Apr 4, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.70 | Apr 1, 2016 | A | 24,000 | A | — | Apr 1, 2026 | Common Stock | 24,000 | 24,000 | D |
| Stock Option (Right to Buy)F2 | $6.70 | Apr 1, 2016 | A | 3,841 | A | — | Apr 1, 2026 | Common Stock | 3,841 | 3,841 | D |
Explanation of responses
- F1Stock option shall vest over a three-year period beginning on March 3, 2016 on a monthly basis in arrears, provided that as of each such vesting date, the Reporting Person continues to provide services to the Company. All unvested shares shall become fully vested upon a change in control of the Company.
- F2The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement. 367 shares of the stock option shall be vested as of April 1, 2016 and the remaining stock option shall vest over the remainder of the 2016 calendar year starting from April 1, 2016 on a quarterly basis in arrears.